Related Experiment Videos
[Antithrombotic therapy in cerebrovascular disorders]
1Medisinsk avdeling Aker sykehus, Oslo.
Summary
Warfarin is recommended for primary and secondary prevention of thromboembolism in patients with non-valvular atrial fibrillation over 60 or with risk factors. Aspirin is an alternative for those with contraindications.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Context:
- Guideline recommendations for stroke prevention.
- Focus on non-valvular atrial fibrillation (NVAF) and thromboembolic risk.
- Management of ischemic stroke and transient ischemic attacks (TIAs).
Purpose:
- To outline prophylactic anticoagulant and antiplatelet therapy guidelines.
- To define patient populations for warfarin and aspirin use.
- To address the role of anticoagulation in progressive ischemic stroke and embolism.
Summary:
- Warfarin is indicated for primary and secondary prophylaxis in NVAF patients >60 years or with risk factors.
- Aspirin is recommended for patients with contraindications to warfarin.
- Antiplatelet therapy shows a ~25% reduction in subsequent stroke risk for TIAs and minor strokes, and is likely indicated for acute, stable ischemic stroke.
Impact:
- Informs clinical practice for stroke prevention strategies.
- Highlights the importance of tailored anticoagulant and antiplatelet therapy.
- Provides evidence-based recommendations for managing thromboembolic events in specific patient groups.